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Abstract Autoantibodies to topoisomerase I (topo I), RNA
polymerase III (RNAPIII), centromere, U3RNP/fibrillarin,
Th, PM-Scl, and U1RNP found in scleroderma (SSc) are
associated with unique clinical subsets. The effects of race
and gender on autoantibody prevalence and clinical
manifestations were examined. Autoantibodies in sera from
105 SSc (include 75 Caucasian, 24 African-American, 6
others; 89 females and 16 males) were analyzed by
immunofluorescence and immunoprecipitation. Clinical
information was from database. SSc-related autoantibodies
seldom coexist except for anti-topo I and anti-U1RNP. Anti-
topo I (35% vs 15%), anti-U3RNP (30% vs 3%, p=0.0005),
and anti-U1RNP (30% vs 13%) were more common in
African-Americans vs Caucasians. Anti-centromere (17%)
and anti-PM-Scl (only in 8% of female) were found only in
Caucasians. In race/gender combination, all three African-
American males had anti-topo I (p=0.04). Anti-U3RNP (35%
vs 3%, p=0.0005) and anti-U1RNP were common in
African-American females. In African-American, all nucleo-
lar dominant staining sera had anti-U3RNP; nuclear pattern
was topo I (50%), U1RNP (19%), and RNAPIII (13%). In
Caucasian, nucleolar was anti-Th (43%) and PM-Scl (29%);
nuclear pattern was RNAPIII (29%), topo I (24%), and
U1RNP (18%). Anti-topo I, anti-RNAPIII, and anti-U3RNP
were associated with diffuse SSc while anti-centromere,
anti-Th, and anti-U1 with limited disease. Proximal sclero-
derma was less common in African-American with anti-topo
I (38% vs 91% in Caucasian, p=0.04). The production of
SSc-related autoantibodies is gender and race dependent, and
this can be highly relevant in understanding their clinical
significance.
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Introduction
Specific autoantibodies in systemic autoimmune rheumatic
diseases are useful biomarkers associated with certain
diagnoses and/or unique clinical manifestations [1, 2].
Several autoantibodies, including anti-topoisomerase I
(topo I), anti-centromere (ACA), anti-RNA polymerase III
(RNAPIII), U3RNP/fibrillarin, Th/To, and PM-Scl, have
been reported to be associated with scleroderma (systemic
sclerosis, SSc); each of these is associated with certain
clinical features and defines a unique clinical subset [1, 3, 4].
Anti-topo I, RNAPIII, and U3RNP are associated with
diffuse scleroderma whereas anti-centromere and anti-Th
are associated with limited scleroderma. Examples of strong
association of SSc-related autoantibodies and clinical
manifestations include anti-topo I with severe interstitial
lung disease (ILD) and RNAPIII with scleroderma renal
crisis [3, 4]. Thus, identifying autoantibodies is clinically
useful not only in helping diagnosis but also in predicting
development of certain clinical manifestations and prognosis
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[2, 4]. However, significant differences in prevalence
and specificity of autoantibodies and clinical features in
SSc patients depending on race and ethnicity have been
reported [3, 5]. Anti-centromere antibodies can be deter-
mined by immunofluorescence antinuclear antibody (ANA)
test alone [2]. Anti-topo I ELISA has been used widely in
clinical practice although difference in specificity illustrated
by high prevalence of anti-topo I in systemic lupus
erythematosus patients in some reports [6, 7] is a concern
[1, 8]. Anti-RNAPIII ELISA was approved by FDA a few
years ago and has been used more and more as indicated by
the increasing number of published papers using anti-
RNAPIII ELISA kit [2, 9]. However, availability of tests
for other autoantibody specificities is limited. Thus, despite
reported racial difference and differences even within
Caucasians of different ethnicity in prevalence of SSc-
related autoantibodies, comprehensive studies that include
most of SSc-related autoantibodies are limited to data
available from small numbers of institutes [3, 5]. In the
present study, the prevalence of SSc-related autoantibodies
and associated clinical features were characterized comparing
different race and gender.
Materials and methods
Patients
From patients enrolled to the University of Florida Center for
Autoimmune Diseases (n=1,542) registry during 2000–2008,
105 patients (Caucasian 75, African-American 23, Latin 5,
Asian 1, mixed 1; 89 females and 16 males) who fulfilled the
ACR SSc classification criteria [10] were studied. Mixed
connective tissue disease (MCTD) or overlap syndrome that
fulfills the criteria for more than one systemic autoimmune
rheumatic disease was not separated from SSc. Clinical
information was from the database and medical record.
Interstitial lung disease was defined by chest X-ray or high-
resolution computed tomography. The protocol was approved
by the Institutional Review Board. This study meets and is in
compliance with all ethical standards in medicine, and
informed consent was obtained from all patients according
to the Declaration of Helsinki.
Autoantibody analysis
Autoantibodies in sera from the initial visit of each patient
were analyzed by immunofluorescence and immunoprecip-
itation. Immunofluorescence antinuclear antibodies (ANA,
HEp-2 ANA slides; INOVA Diagnostics, San Diego, CA,
USA) were performed using a 1:80-diluted serum followed
by FITC goat anti-human IgG (γ-chain specific, Southern
Biotechnology, Birmingham, AL, USA). Analysis of
protein components of autoantigens were by immunopre-
cipitation of 35S-methionine-labeled K562 cell extract and
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) on 8% and 12.5% acrylamide SDS-PAGE
[11]. RNA components were analyzed by immunoprecipi-
tation of unlabeled K562 cells, urea-PAGE, and silver
staining (Silver Stain Plus, Bio-Rad, Hercules, CA, USA)
[5]. Specificities of autoantibodies were determined using
reference sera.
Statistical analysis
Prevalence of autoantibodies or clinical manifestations was
compared by Fisher’s exact test using Prism 4.0c for
Macintosh (GraphPad Software, Inc., San Diego, CA,
USA). P<0.05 was considered significant.
Results
SSc-related autoantibodies were determined using immu-
nofluorescence and immunoprecipitation. Prevalence of
autoantibodies is summarized in Table 1.
Totala Caucasian American African-American Latin American
N 105 75 23 5
Male, % 15 17 13 0
Age (mean±SD) 50.6±13.3 52.4±12.1 47.5±15.9 41.8±15.4
Topo I 19% (20/105) 15% (11/75)1 35% (8/23)1,2 20% (1/5)
RNAP III 16% (17/105) 19% (14/75) 9% (2/23) 0%
Centromere 14% (15/105) 17% (13/75)3 03,4 40% (2/5)
U3RNP 9% (9/105) 3% (2/75)5 30% (7/23)5 0%
Th 8% (8/105) 9% (7/75) 4% (1/23) 0%
U1RNP 18% (19/105) 13% (10/75)6 30% (7/23)6 40% (2/5)
PM-Scl 5% (5/105) 6% (5/75) 0% 0%
None of the above 17%(18/105) 20% (15/75) 9% (2/23) 0%
Table 1 Prevalence of autoanti-
bodies in Caucasian, African-
American, and Latin American
patients with scleroderma
1 p=0.07; 2 p=0.04 vs non-
African-American; 3 p=0.03;
4 p=0.04 vs non-African-
American; 5 p=0.0005; 6 p=0.11
a Total includes one each of Asian
and mixed patient in addition to
Caucasian, African-American, and
Latin
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Prevalence of autoantibodies in different race
Anti-topo I was the most common specificity (35%) in
African-Americans, and also this was more prevalent than
other race (p=0.07 vs Caucasian, p=0.04 vs non-African-
American). Anti-RNAPIII (19%) was the most common in
Caucasians followed by ACA (17%) and anti-topo I (15%).
Although the numbers of non-Caucasian patients are small,
ACA (p=0.03 vs African-American) was not found in
African-Americans. Anti-PM-Scl (6%) antibodies were
found only in Caucasian, and seven of eight cases of anti-
Th were also Caucasian. In contrast, anti-U3RNP (30% vs
3% in Caucasian, p=0.0006) and anti-U1RNP (30% vs
13% in Caucasian) were as common as anti-topo I in
African-Americans. As a total, 80% of Caucasian, 91% of
African-American, and 100% of Latin SSc patients had one
or more SSc-related autoantibodies on the list.
Race, ANA patterns, and autoantibody specificities
African-American and Caucasian SSc patients were
grouped based on the immunofluorescent patterns: nucleo-
lar dominant, nuclear dominant, centromere, and cytoplas-
mic. Many sera have more than one of the nuclear,
nucleolar, or cytoplasmic staining, but sera were classified
based on the brightest staining pattern when 1:80 diluted
sera were tested. Majority of sera were classified as nuclear
or nucleolar and dominant cytoplasmic staining was
uncommon. Percentage of specific autoantibodies detected
in each group is shown (Fig. 1). In African-Americans, all
seven nucleolar dominant staining sera were anti-U3RNP.
In striking contrast, anti-Th (43%) and PM-Scl (29%) were
the most common for nucleolar staining dominant sera in
Caucasians. For nuclear dominant pattern, 50% had anti-
topo I, 19% had anti-U1RNP (Note: Patients with both anti-
topo I and U1RNP were in anti-topo I group in this
analysis), and RNAPIII 13% in African-Americans whereas
in Caucasians anti-RNAPIII (29%) was the most common
followed by topo I (24%) and U1RNP (18%). In our cohort,
ACA was found only in 17% of Caucasian and not in
African-American (Table 1). These data indicate that
common specificities that can be expected based on the
ANA patterns are quite different between African- and
Caucasian-Americans and that considering race and ANA
patterns will be helpful to predict specific autoantibodies
even when specific test results are not available.
Coexistence of other scleroderma-related autoantibodies
Prevalence of SSc-related autoantibodies comparing Caucasian-,
African-, and Latin-Americans is summarized (Table 1).
Coexistence of more than one SSc-related autoantibodies
was very unusual except for coexistence of anti-U1RNP and
anti-topo I antibodies (6 of 20, 30%, p=0.0012 vs all other
SSc-related autoantibodies, Fisher’s exact test), consistent
with previous literatures [3, 12]. Anti-U1/U2RNP antibodies
with unusual U2RNP dominant reactivity were found in one
anti-RNAP III-positive patient (Fig. 2).
Prevalence of autoantibodies in patients with scleroderma
classified by race and gender
Since gender may also affect autoantibody specificities,
gender difference in each race is analyzed (Table 2). Anti-
topo I was positive in all three male African-American
patients (p=0.04 vs Caucasian male, p=0.004 vs Caucasian
female). Anti-U3RNP, anti-Th, and anti-PM-Scl (Caucasians
only) were found only in female, and all except one (1 of 18)
anti-U1RNP were also female. Anti-U3RNP was the most
common specificity in African-American female (35% vs
3% in Caucasian female, p=0.0005, p=0.03 vs Caucasian
male), and anti-U1RNP was also more common in African-
American (35% vs 16% in Caucasians). ILD (Caucasians vs
Fig. 1 Prevalence of autoantibodies in scleroderma patients classified
based on race and patterns of immunofluorescence antinuclear
antibodies. ANA patterns were classified based on the dominant
immunofluorescence staining pattern using 1:80 diluted sera. Patients
with both anti-topo I and U1RNP were classified in anti-topo I group
in this analysis
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African-Americans, p=0.07; Caucasian female vs African-
American female, p=0.07) and PH may be more prevalent in
African-Americans while renal crisis appeared to be more
common in Caucasians, even if they did not reach statistical
significance.
Race, autoantibodies, and clinical manifestations
Prevalence of proximal scleroderma (Table 3), ILD (Table 4),
renal crisis, and pulmonary hypertension (not shown) in SSc
classified by race and autoantibodies was analyzed. In
general, association of specific autoantibodies and preva-
lence of proximal scleroderma was consistent with previous
literature [3, 4]: anti-topo I, RNAPIII, and U3RNP with
diffuse skin involvement; ACA, anti-Th, and U1RNP with
limited skin involvement (Table 3). The only significant
difference was the low prevalence of proximal scleroderma in
African-Americanwith anti-topo I (38% vs 91% in Caucasian,
p=0.04). This was related to a subset of patients in this
group: four out of eight had anti-topo I and U1RNP and
three out of four of them had no sclerodermatous changes.
Prevalence of ILD was the highest in anti-topo I-positive
patients (p=0.04 vs ACA) and relatively low in anti-
RNAPIII patients, consistent with literature (Table 4) [3, 4].
ILD in anti-U1RNP-positive African-American was 86%
(six of seven); however, four of them also had anti-topo I,
all with ILD.
Scleroderma renal crisis was significantly associated
with anti-RNAPIII as documented in literature (p=0.002 vs
anti-RNAPIII negative, p=0.02 vs ACA group) [3, 4], seen
in 35% in total and 43% in Caucasian patients. PH was
seen in 26% of African-Americans and 17% of Caucasians,
but association with race or autoantibodies was not
statistically significant (not shown).
Discussion
High specificity of certain autoantibodies, such as anti-topo
I and anti-RNAPIII, for the diagnosis of SSc is well
Fig. 2 Rare coexistence of scleroderma-related autoantibodies.
Pattern of distribution of SSc-related autoantibodies is shown. Black
circle indicates the cases of anti-U1RNP positives that coexist with
anti-topo I (six cases) or anti-RNAPIII (one case)
Table 2 Prevalence of autoantibodies and clinical manifestations in different race and gender
Race Caucasian American African-American Latin American
Gender Female Male Female Male Female
N 62 13 20 3 5
Age (mean±SD) 51.1±12.1 58.8±10.3 46.1±16.5 56.6±6.2 41.8±15.4
Topo I 13%1 (8/62) 23%2 (3/13) 25% (5/20) 100%1,2 (3/3) 20% (1/5)
RNAP III 18% (11/62) 23% (3/13) 10% (2/20) 0% 0%
Centromere 16%3 (10/62) 23% (3/13) 0%3 0% 40% (2/5)
U3RNP 3%4 (2/62) 0%5 35%4,5 (7/20) 0% 0%
Th 11% (7/62) 0% 5% (1/20) 0% 0%
U1RNP 16%6 (10/62) 0% 35%6,7 (7/20) 33% (1/3) 40% (2/5)
PM-Scl 8% (5/62) 0% 0% 0% 0%
None of the above 18% (11/62) 31% (4/13) 10% (2/20) 0% 0%
Proximal scleroderma 50% (31/62) 62% (8/13) 55% (11/20) 67% (2/3) 60% (3/5)
ILD8 37%9 (23/62) 46% (6/13) 65%9 (13/20) 67% (2/3) 40% (2/5)
Renal crisis 15% (9/62) 8% (1/13) 5% (1/20) 0% (0/3) 0%
Pulmonary hypertension 15% (10/62) 23% (3/13) 25% (5/20) 33% (1/3) 0%
ILD interstitial lung disease
1 p=0.004; 2 p=0.04; 3 p=0.11; 4 p=0.0005; 5 p=0.03; 6 p=0.11; 7 p=0.04 vs Caucasian; 8 p=0.03, Caucasian vs African-American; 9 p=0.07, ILD
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established [1, 3] as evidenced by many studies and by the
inclusion of these autoantibodies in the proposal of
classification criteria of SSc [13, 14]. Target autoantigens
and their biological functions recognized by SSc-related
autoantibodies are well characterized [15]. Significant
progress has been made in understanding genetics and
immunopathogenesis of autoantibody production in general
[16]. Nevertheless, the mechanisms and reasons of associ-
ation between the production of specific autoantibodies and
certain diagnosis or clinical manifestations are still poorly
understood, other than the general consensus that both
genetic and environmental factors play a role in the
production of specific autoantibodies [16, 17].
Data in the present study including rare coexistence of
SSc-related autoantibodies; higher prevalence of anti-topo
I, U3RNP, and U1RNP in African-American; and higher
prevalence of anti-RNAPIII, centromere, Th, and PM-Scl in
Caucasians are consistent with previous literature [3].
Association of autoantibodies with limited vs diffuse skin
involvement in the present study is also consistent with
virtually all other studies regardless the location of the
studies or ethnicity of the cohort, further supporting
universal association of these autoantibodies with SSc
subset: anti-topo I, anti-RNAPIII, anti-U3RNP, and anti-
PM-Scl with diffuse cutaneous involvement vs ACA, anti-
Th, and anti-U1RNP with limited cutaneous involvement
[3, 18].
Race-ANA pattern-specific autoantibodies analysis
(Fig. 1) may seem overly simplified since many sera have
more than one location in the stained cells. Nevertheless,
this may be similar to what many clinicians actually receive
as a test report of clinical samples. We and others reported
that anti-RNAPI/III sera are seldom reported as nucleolar
staining positive despite biological localization of RNAPI
to nucleoli and detection of nucleolar staining in many sera
of this group by careful examination [4, 9, 19]. As expected
and consistent with our previous study, anti-U3RNP (nine
of nine), anti-Th (six of eight), and anti-PM-Scl (four of
five) had nucleolar dominant pattern [19]. There are fine
differences within staining by different antinucleolar anti-
bodies [20]. Also, typically nuclear staining by anti-
RNAPIII vs topo I is distinct, the former in moderate size
speckled whereas the latter is fine speckled to homoge-
neous staining. Thus, with reading by an expert, nucleolar
and nuclear staining patterns can be further classified and
may be correlated with specific autoantibodies as illustrated
in the recent articles [20, 21]. However, this is beyond the
ability of most clinical laboratories and what we showed in
this simplified analysis may be more practical. It is clear
that potential autoantibody specificities can be narrowed
All Caucasian American African-American Latin American
N 105a 75 23 5
Total 54% (57/105) 52% (39/75) 57% (13/23) 60% (3/5)
Topo I 70% (14/20) 91% (10/11)* 38% (3/8)* 1/1
RNAP III 81% (13/16) 71% (10/14) 100% (2/2) NA
Centromere 20% (3/15) 15% (2/13) NA 1/2
U3RNP 78% (7/9) 50% (1/2) 86% (6/7) NA
Th 38% (3/8) 43% (3/7) 0/1 NA
U1RNP 32% (6/19) 30% (3/10) 29% (2/7) 1/2
PM-Scl 60% (3/5) 60% (3/5) NA NA
None of the above 61% (11/18) 60% (9/15) 1/2 NA
Table 3 Prevalence of proximal
scleroderma in scleroderma
patients classified by race and
autoantibodies
NA not applicable
*p=0.04
a Includes one each of Asian and
mixed patient
All Caucasian American African-American Latin American
N 105a 75 23 5
Total 44% (46/105) 39%* (29/75) 65%* (15/23) 40% (2/5)
Topo I 70%** (14/20) 64% (7/11) 75% (6/8) 1/1
RNAP III 41% (7/17) 43% (6/14) 1/2 NA
Centromere 33%** (5/15) 31% (4/13) NA 1/2
U3RNP 33% (3/9) 0% (0/2) 43% (3/7) NA
Th 25% (2/8) 29% (2/7) 1/1 NA
U1RNP 53% (10/19) 40% (4/10) 86% (6/7) 0/2
PM-Scl 20% (1/5) 20% (1/5) NA NA
None of the above 50% (9/18) 47% (7/15) 2/2 NA
Table 4 Prevalence of interstitial
lung disease in scleroderma
patients classified by race and
autoantibodies
NA not applicable
*p=0.06; **p=0.04
a Includes one each of Asian and
mixed patient
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down very efficiently by considering race and dominant
ANA pattern. Since tests for nucleolar antibodies such as
anti-U3RNP and anti-Th are not readily available for most
clinicians, keeping this chart in mind and carefully
examining ANA pattern may be useful.
Coexistence of SSc-related autoantibodies, in particular
when tested by immunodiffusion or IP as further confirmed
in the present study (Fig. 2; vs studies primarily using
ELISA), is uncommon [3]. The only exception is the
coexistence of anti-topo I and U1RNP, which has also been
described in literature [12].
Low prevalence of proximal scleroderma in African-
Americans (Table 2) is somewhat unexpected compared
with literature [12]; however, there are several possible
explanations. Selection of patients and definition of SSc
may be a factor. African-American population in the
present study includes a subset of patients who had anti-
topo I with U1RNP and RP, pitting scars, ILD but no or
limited sclerodermatous changes, since SSc was defined
and selected purely based on the ACR SSc classification
criteria in the present study. However, cases like these may
not be included in other SSc studies. In studies from the
University of Pittsburgh, selection of SSc was based on
diagnosis by physicians; thus, only 86–88% of their study
population fulfill the ACR SSc criteria [12, 22, 23]. In other
studies, sclerodactyly was the requirement for selection of
study patients [24] or criteria by LeRoy et al. [25] were
used [26]. Thus, the selected SSc patients may not include
patients with RP with pitting scars and ILD as in our study.
This selection bias alone may explain some differences
reported in the clinical studies of SSc patients selected based
on the different criteria. In a recent large epidemiological
study in SSc, bias due to difference in patient recruitment
was considered a likely explanation of large variability of
SSc presentation between centers or even within a single city
[17]. Another consideration is the definition and categori-
zation of patients with MCTD and overlap syndromes [27].
How these groups of patients are handled is not clearly
stated in all SSc studies. However, whether the studied SSc
cohort includes MCTD or overlap syndromes will signifi-
cantly affect the prevalence of certain autoantibodies such
as anti-U1RNP, PM-Scl, and Ku, which are often seen in
SSc patients with overlapping features and clinical analysis
[3]. If MCTD or overlap syndromes are defined as a
separate category, patients with anti-U1RNP and anti-topo I
can be easily classified as MCTD as suggested by reports
on detection of anti-topo I in patients with MCTD [28, 29].
Another potential difference in the present study was the
production of anti-U3RNP, Th, and PM-Scl only in female
patients (Table 2). Increased percentage of male patients in
anti-Th-positive SSc in Caucasians reported in some studies
[5] was not observed in this study. The number of male SSc
patients was small in the present study; nevertheless,
heterogeneity in patients’ population within race may be
another factor as discussed below. In clinical studies,
ethnicity is usually classified into Caucasian, African-
American, Latin, Asian, Native American, etc. Although
this is probably the best we can do practically, each
category of race is quite heterogeneous and is a mixture
of people with different ethnic background in different
ratios, in particular in the USA. For example, Caucasians in
the USA includes people originally from anywhere in
Europe and also Jewish population. This population may be
quite different from studies performed in a single European
country where Caucasian population is relatively homoge-
neous. This could be a part of the reason for high
prevalence of anti-RNAPIII in Caucasians in the USA vs
low prevalence in French or Italian studies [5, 30–32]. Of
course, differences in environmental factors, which can
never be clearly separated, complicate the issue. Caucasians
and African Americans in the USA have different ethnic
background depending on the location of the study.
In summary, both race and gender impact the prevalence
of SSc-related autoantibodies substantially. Based on ANA
pattern and race, specific autoantibodies can be predicted
and tested efficiently. The data suggest that multiple genetic
and/or environmental factors may play a role in the
production of specific autoantibodies. This may also help
to explain the infrequent coexistence of more than one of
the SSc-related autoantibodies in a single patient’s serum.
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